Robbins LLP Urges BBNX Stockholders to Contact the Firm for Information About the Class Action Against Beta Bionics, Inc.

Robbins LLP issued a solicitation reminding BBNX investors of the November 3, 2026 lead plaintiff deadline in a securities class action against Beta Bionics covering purchases from July 30, 2025 through February 24, 2026. The complaint alleges defendants misled investors about FDA Form 483 findings on the iLet insulin pump, with the FDA warning letter released February 24, 2026 alleging device malfunctions causing hypoglycemic events.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.